Prevalence of human papillomavirus types 6, 11, 16, 18, 31, and 33 in a cohort of Greek women

Journal of Medical Virology

Volumn 79, Issue 12, 2007, Pages 1898-1905

  Panotopoulou, Efstathia ^a   Tserkezoglou, Aliki ^a   Kouvousi, Maria ^a   Tsiaousi, Ioanna ^a   Chatzieleftheriou, George ^a   Daskalopoulou, Demitra ^a   Magiakos, George ^a  

^a Regional Anticancer Oncology Hospital of Athens St Savvas   (Greece)

Author keywords

Cervical cancer; Cytological examination; HPV

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTODIAGNOSIS; FEMALE; GREECE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; SUPERINFECTION; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS IDENTIFICATION; WART VIRUS;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; COHORT STUDIES; FEMALE; GREECE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL DISEASES;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES;

EID: 35549000034     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21025     Document Type: Article

References (44)

1. Agorastos T, Bontis J, Lambropoulos AF, Constantinidis TC, Nasioutzini M, Tagou C, Katsouyiannopoulos V. 1995. Epidemiology of human papillomavirus infection in Greek asymptomatic women. Eur J Cancer Prev 4:159-167.
2. Agorastos T, Dinas K, Lioveras B, Bosch FX, Kornegay JR, Bontis JN, deSanjosé S. 2004. Cervical human papillomavirus infection in women attending gynaecological outpatient clinics in Northern Greece. Eur J Cancer Prev 13:145-147.
3. Agorastos T, Dinas K, Lioveras B, Font R, Kornegay JR, Bontis J, de Sanjose S. 2005. Self sampling versus physician-sampling for human papillomavirus testing. Int J STD AIDS 16:727-729.
4. Bohmer G, van den Brule AJ, Brummer O, Meijer CL, Petry KU. 2003. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol 189:118-120.
5. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. 1995. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer I 87:796-802.
6. Bosch FX, Qiao Y-L, Castellsaqué X. 2006. The epidemiology of human papillomavirus infection and its association with cervical cancer. Int J Gynecol Obstet 94:S8-S21.
7. Bray F, Loss AH, McCarron P, Weiderpass E, Arbyn M, Moller H, Hakama M, Parkin DM. 2005. Trends in squamous cell carcinoma incidence in 13 European countries: Changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 14:677-686.
8. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2006. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer I 98: 303-315.
9. Clifford GM, Smith JS, Aguado T, Franceschi S. 2003. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 89:101-105.
10. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. 2005. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14:1157-1164.
11. Davies P, Arbyn M, Dillner J, Kitchener HC, Meijer CJ, Ronco G, Hakama M. 2006. A report on the current status of European research of the use of human Papillomavirus testing for primary cervical cancer screening. Int J Cancer 118:791-796.
12. de Roda Husman AM, Wallboomers M, van den Brule AJC, Meijer CJLM, Snijders PJF. 1995. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human Papillomavirus detection by PCR. J Gen Virol 76:1057-1062.
13. Dokianakis DN, Papaefthimiou M, Tsiveleka A, Spandidos D. 1999. High prevalence of HPV 18 in correlation with ras gene mutations and clinicopathological parameters in cervical cancer studied from cervical cytological smears. Oncol Rep 66:1327-1331.
14. Elbasha EH, Dasbach EJ, Insinga RP. 2007. Model for assessing human papilomavirus vaccination strategies. Emerg Infect Dis 13:28-41.
15. Franco EL, Harper DM. 2005. Vaccination against human papillomavirus infection: A new paradigm in cervical cancer control. Vaccine 23:2388-2394.
16. Gargiulo F, De Francesco MA, Schreiber C, Ciravolo G, Salinaro F, Valloncini B, Manca N. 2007. Prevalence and distribution of single and multiple HPV infections in cytologically normal and abnormal cervical samples from Italian women. Virus Res 10.10166 (in press).
17. Jacobs MV, de Roda Husman AM, van den Brule AJ, Meijer CJ, Sjniders PJ, Wallboomers JM. 1995. Group- specific differentiation between high- and low-risk human Papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probe. J Clin Microbiol 33:901-905.
18. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ. 2000. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types. Int J Cancer 87:221-227.
19. Jones HW III. 1995. Impact of the Bethesda System. Cancer 76:1914-1918.
20. Klug S, Hukelmann M, Hollwitz B, Duzenli N, Schoop B, Petry KU, Iftner T. 2007. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 79:616-625.
21. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. 2007. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomised studies. Gynecol Oncol 104:232-246.
22. Konidaris S, Kouskouni EE, Panoskaltsis T, Kreatsas G, Patsouris ES, Sarivalassis A, Nonni A, Lazaris AC. 2007. Human papillomavirus infection in malignant and benign gynaecological conditions: A study in Greek women. Health Care Women Int 28:182-191.
23. Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. 2001. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: A study of 49 cases. Cancer 93:8-15.
24. Kruger-Kjaer S, van der Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME. 1997. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Rap smear: Are there different risk profiles for oncogenic and nononcogenic HPV types. Cancer Epidemiol Biomark Prev 6:799-805.
25. Kulasingam SL, Myers ER. 2003. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290:781-789.
26. Labropoulou V, Diakomanolis E, Dailianas S, Kalpaktsoglou K, Balamotis A, Mavromara P. 1997. Type-specific prevalence of genital human papillomaviruses in benign, premalignant and malignant biopsies in patients from Greece. Sexually Transmitted Diseases 24:469-474.
27. Lacey CJ, Lowndes CM, Shah KV. 2006. Chapter 4: Burden and management of non-cancerous HPV related conditions: HPV 6/11 disease. Vaccine 24:S35-41.
28. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA. 1999. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for Equivocal Papanicolaou Results. JAMA 281C170:1605-1610.
29. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
30. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. 2006. Chapter 1: HPV in the etiology of human cancer. Vaccine 24:S1-S10.
31. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. 2000. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151: 1158-1171.
32. Pao CC, Lin C-Y, Maa J-S, Lai C-H, Wu S-Y, Soong Y-K. 1990. Detection of human papillomavirus in cervicovaginal cells using polymerase chain reaction. J Infect Dis 161:113-115.
33. Parkin DM, Bray F. 2006. Chapter 2: The burden of HPV-related cancers. Vaccine 24:S11-25.
34. Parkin DM, Bray F, Ferlay J, Pisani P. 2001. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-1566.
35. Ronco G, Ghisetti V, Segnan N, Snijders P, Gillio-Tos A, Meijer C, Merletti F, Franceschi S. 2005. Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 41:297-305.
36. Sankaranarayanan R, Nene BM, Dinshaw KA, Mahe C, Jayant K, Shastri SS, Malvi SG, Chinoy R, Kelkar R, Budukh AM, Keskar V, Rajeshwarker R, Muwonge R, Kane S, Parkin DM, Chauhan MK, Desai S, Fontaniere B, Frappart L, Kothari A, Lucas E, Panse N, Osmanabad District Cervical Screening Study Group. 2005. A cluster randomized controlled trial of visual cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 116:617-623.
37. Schoolland M, Segal A, Allpress S, Miranda A, Frost FA, Sterrett GF. 2002. Adenocarcinoma in situ of the cervix. Cancer 96:330-337.
38. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high grade cervical lesions: A meta-analysis update. Int J Cancer 121:621-632.
39. van den Brule AJ, Meijer CJ, Bakels V, Kenemans P, Wallboomers JM. 1990. Rapid detection of human papillomavirus in cervical scrapes by combined general-primer mediated and type-specific polymerase chain reaction. J Microbiol 28:2739-2743.
40. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meyer CJ, Sjniders PJ. 2002. GP5+/GP6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human Papillomavirus genotypes. J Microbiol 40:779-787.
41. Vassilandonopoulou G, Panotopoulou E, Fotiou S, Tserkezoglou A, Machera E, Kottaridis S. 1997. Human papillomaviruses in cervical cancer I. HPV-16 and 18 predominate in the Greek population. Anticancer Res 17:117-120.
42. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11,16 and 18) Li virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multi-centre phase II efficacy trial. Lancet Oncol 6:271-278.
43. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
44. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. 2004. Cervical cancer as a priority for prevention in different world regions: An evaluation using years of life lost. Int J Cancer 109:418-424.